Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 18/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4049214 | 0.94 | PARP1 (0.68) | PARP1CYP1A2MAPK1 | |
| SCHEMBL4048930 | 0.88 | PARP1 (0.64) | PARP1CYP1A2PARP2 | |
| SCHEMBL4052965 | 0.86 | PARP1 (0.71) | PARP1CYP1A2 | |
| SCHEMBL4049162 | 0.85 | PARP1 (0.69) | PARP1CYP1A2 | |
| SCHEMBL4056579 | 0.84 | PARP1 (0.71) | PARP1CYP1A2 | |
| SCHEMBL4045743 | 0.84 | PARP1 (0.68) | PARP1CYP1A2 | |
| SCHEMBL4050808 | 0.83 | PARP1 (0.70) | PARP1CYP1A2 | |
| SCHEMBL4048087 | 0.83 | PARP1 (0.69) | PARP1CYP1A2 | |
| SCHEMBL4054379 | 0.82 | PARP1 (0.73) | PARP1CYP1A2 | |
| SCHEMBL4054673 | 0.80 | PARP1 (0.67) | PARP1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069351-B1 | PYRAZOLOQUINAZOLINONES AS PARP INHIBITORS | ABBVIE INC (US) | 2015-10-28 | — | — | EP | claimed |
| US-8183250-B2 | Potent PARP inhibitors | ABBOTT LABORATORIES (US) | 2012-05-22 | — | — | US | claimed |
| US-20090298858-A1 | POTENT PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2009-12-03 | — | — | US | claimed |
| EP-2069351-A2 | PYRAZOLOQUINAZOLINONES AS PARP INHIBITORS | Abbott Laboratories (US) | 2009-06-17 | — | — | EP | claimed |
| US-20080015182-A1 | Potent PARP Inhibitors | ABBOTT LABORATORIES | 2008-01-17 | — | — | US | claimed |
| WO-2007149907-A2 | PYRAZOLOQUINAZOLINONES AS PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2007-12-27 | — | — | WO | claimed |
| EP-2069351-B1 | PYRAZOLOQUINAZOLINONES AS PARP INHIBITORS | ABBVIE INC (US) | 2015-10-28 | — | — | EP | disclosed |
| US-8183250-B2 | Potent PARP inhibitors | ABBOTT LABORATORIES (US) | 2012-05-22 | — | — | US | disclosed |
| US-20090298858-A1 | POTENT PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2009-12-03 | — | — | US | disclosed |
| EP-2069351-A2 | PYRAZOLOQUINAZOLINONES AS PARP INHIBITORS | Abbott Laboratories (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20080015182-A1 | Potent PARP Inhibitors | ABBOTT LABORATORIES | 2008-01-17 | — | — | US | disclosed |
| WO-2007149907-A2 | PYRAZOLOQUINAZOLINONES AS PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298858-A1 | POTENT PARP INHIBITORS | PARP1, PARP2, PARP3 | PARP1 1/4885CYP1A2 782/4885PARP2 2/4885 |
| US-20080015182-A1 | Potent PARP Inhibitors | PARP1, PARP2, PARP3 | PARP1 1/4885CYP1A2 782/4885PARP2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.